New Phase 3 trial: A Study to Compare GNR-139 and Eylea® in Patients With nAMD — AO GENERIUM
Why now
Thesis: Early trial, no near-term market impact
Catalyst to watch: Trial enrollment or interim data
Main risk: Trial failure or slow enrollment
Why it matters
A new nAMD biosimilar-style trial could pressure Eylea's franchise if aflibercept competition expands, but it is early-stage and sponsor-specific.
Details
Sponsor: AO GENERIUM; Status: Recruiting; Conditions: nAMD; Interventions: aflibercept, Eylea; Enrollment: 180 (estimated); First posted: 2026-09-28; NCT: NCT07844148
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-28 12:00 UTC